The US FDA maintained a torrid approval pace, capping the week with three novel approvals on Friday Aug. 10 to bring the Center for Drug Evaluation and Research’s (CDER's) annual count to 30.
Orphan diseases dominated the approved indications. Kyowa Hakko Kirin Co. Ltd.’s Poteligeo (mogamulizumab-kpkc), for two rare types of cutaneous...








